Dyne Therapeutics Inc. (NASDAQ: DYN) has initiated its Phase 3 HARMONIA trial evaluating z-basivarsen for myotonic dystrophy type 1, according ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE